Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00118235 · ClinicalTrials.gov registry record · Phase 2

Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer

A Phase 2 study of Extensive-stage Small-cell Lung Cancer, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
72
Enrollment target
2
Study locations

NCT00118235 is a Phase 2 study of Extensive-stage Small-cell Lung Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 72 participants, below the 173-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (58% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00118235, a Phase 2 study of Extensive-stage Small-cell Lung Cancer, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
72 participants
Enrollment target
2
Study locations

Study Summary

This phase II trial is studying how well giving cisplatin and irinotecan together with bevacizumab works in treating patients with extensive-stage small cell lung cancer. Drugs used in chemotherapy, such as cisplatin and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of small cell lung cancer by blocking blood flow to the tumor. Giving cisplatin and irinotecan together with bevacizumab may kill more tumor cells.

Conditions Studied

Extensive-stage Small-cell Lung Cancer

Interventions

  • OTHER laboratory biomarker analysis
  • DRUG cisplatin
  • BIOLOGICAL bevacizumab
  • DRUG irinotecan hydrochloride

Study Locations (2)

Illinois

  • Cancer and Leukemia Group B - Chicago

Rhode Island

  • Rhode Island Hospital - Providence

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2004-12
Est. Completion 2011-07
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00118235

The ClinicalTrials.gov registry entry for NCT00118235 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 173-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (58% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Extensive-stage Small-cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which laboratory biomarker analysis is the first listed.

NCT00118235 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Rhode Island.

Frequently Asked Questions

What is clinical trial NCT00118235 about?

NCT00118235 is a clinical study titled "Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer". This phase II trial is studying how well giving cisplatin and irinotecan together with bevacizumab works in treating patients with extensive-stage small cell lung cancer. Drugs used in chemotherapy, such as cisplatin and irinotecan, work in different ways to stop the growth of tumor cells, either by...

What is the current status of trial NCT00118235?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2004-12. Estimated completion is 2011-07.

What conditions does trial NCT00118235 study?

This clinical trial studies the following conditions: Extensive-stage Small-cell Lung Cancer.

What interventions are being tested in trial NCT00118235?

The interventions under investigation include: laboratory biomarker analysis (OTHER), cisplatin (DRUG), bevacizumab (BIOLOGICAL), irinotecan hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00118235?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00118235 being conducted?

This trial has 2 study locations across Illinois, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Extensive-stage Small-cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Extensive-stage Small-cell Lung Cancer

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.